Compare Fortinet Inc (FTNT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs TransMedics Group Inc — how do they compare? Fortinet Inc trades at $163.56 (market cap $118.78B), while TransMedics Group Inc trades at $87.54 (market cap $3.10B). The key difference: Fortinet Inc is far larger — about 38.3× TransMedics Group Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| FTNT | TMDX | |
|---|---|---|
Market Cap | $118.78B | $3.10B |
Sector | Technology | Technology |
52-Week High | $168.29 | $150.42 |
52-Week Low | $75.23 | $61.99 |
Enterprise Value | $115.21B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $164.21, up 2.86% in the last session, reflecting strong momentum as it approaches its consensus price target of $174.50. The stock exhibits bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $0.90 versus $0.746 expected. Revenue growth remains robust, climbing to $6.80 billion in 2025, with a net income margin of 28.17%. Recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
The outlook is positive, supported by solid fundamentals and analyst optimism, though elevated valuation ratios like a P/E of 57.2 pose risks. Competition and market volatility are concerns, but institutional buying and bullish ratings suggest further upside potential.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
